0001809726-25-000004.txt : 20250922 0001809726-25-000004.hdr.sgml : 20250922 20250922102023 ACCESSION NUMBER: 0001809726-25-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20250922 DATE AS OF CHANGE: 20250922 EFFECTIVENESS DATE: 20250922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Claris Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001809726 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-558173 FILM NUMBER: 251328844 BUSINESS ADDRESS: STREET 1: 299 PAVONIA AVENUE 3-8 CITY: JERSEY CITY STATE: NJ ZIP: 07302 BUSINESS PHONE: 201-344-7638 MAIL ADDRESS: STREET 1: 299 PAVONIA AVENUE 3-8 CITY: JERSEY CITY STATE: NJ ZIP: 07302 D 1 primary_doc.xml X0708 D LIVE 0001809726 Claris Biotherapeutics, Inc. 299 PAVONIA AVENUE 3-8 JERSEY CITY NJ NEW JERSEY 07302 201-344-7638 DELAWARE None None Corporation true Clarke Atwell c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue, 3-8 Jersey City NJ NEW JERSEY 07302 Executive Officer Director Reza Dana c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue, 3-8 Jersey City NJ NEW JERSEY 07302 Director Kenneth Harrison c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue, 3-8 Jersey City NJ NEW JERSEY 07302 Director Marc de Garidel c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue, 3-8 Jersey City NJ NEW JERSEY 07302 Director Meredith Fisher c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue, 3-8 Jersey City NJ NEW JERSEY 07302 Director Henry Rath c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue, 3-8 Jersey City NJ NEW JERSEY 07302 Executive Officer Susan Orr c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue, 3-8 Jersey City NJ NEW JERSEY 07302 Executive Officer Biotechnology Decline to Disclose 06b false 2025-09-12 false true false 0 2300000 2300000 0 false 6 0 0 610000 This estimate is based on the expected time period for R&D/related activities to be funded by the proceeds and the aggregate regular/continuing compensation for these individuals? services during that period. false Claris Biotherapeutics, Inc. /s/ Clarke Atwell Clarke Atwell President & Chief Executive Officer 2025-09-22